Résumé
La TEP au 18FDG présente de nombreuses indications dans l’évaluation des tumeurs digestives. Son rôle principal concerne le bilan d’extension des récidives tumorales démontrées ou suspectées mais des indications plus ponctuelles concernent également le diagnostic différentiel des masses pancréatiques et le bilan initial du cancer de l’œsophage. Le principal avantage de la TEP résulte de la nature métabolique du signal, indépendant et complémentaire des modifications anatomiques visibles en imagerie classique. Un autre avantage est lié à l’examen du corps entier aujourd’hui pratiqué systématiquement. La TEP trouve dès lors sa place en première ligne dans ses différentes indications.
Summary
PET with 18-FDG has numerous indications in the evaluation of patients with gastrointestinal carcinoma. Its principal indications are the staging of suspected or demonstrated recurrent disease and to assess the operability of lesion. Validated indications also concern the differential diagnosis of pancreatic masses and the initial staging of oesophageal cancer.
The metabolic signal of PET constitutes its main advantage. It is independent but complementary to the anatomical changes assessed by structural imaging. Another advantage is related to imaging of the whole-body is now routinely performed. PET can thus be a one step examination in the staging of digestive cancers and is best used early in the staging process.
Article PDF
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Références
WARBURG O. — The metabolism of tumors. Smith RR Inc, New York 1931, 129–169.
ABDEL-NABI H., DOERR R.J.et al. — Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathological and CT findings.Radiology, 1998,206, 755–760.
OGUNBIYI O.A., FLANAGAN F.L., DEHDASHTI F.et al. — Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography.Ann. Surg. Oncol., 1997,4, 613–620.
FALK P.M., GUPTA N.C., THORSON A.G.et al. — Positron emission tomography for preoperative staging of colorectal carcinoma.Dis. Colon. Rectum, 1994,37, 153–156.
GUPTA N., BRADFIELD H. — Role of positron emission tomography scanning in evaluating gastrointestinal neoplasms.Sem. Nucl. Med., 1996,26, 65–73.
LARSON S.M., COHEN A.M., CASCADE M.B.A. — Clinical application and economic implications of PET in the assessment of colorectal cancer recurrence: A retrospective study. Abstract from the 1994 ICP Meeting, Institute for clinical PET, Fairfax, Virginia.
VITOLA J.V., DELBEKE D., SANDLER M.P.et al. — Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver.Am. J. Surg., 1996,171, 21–26.
BEETS G., PENNINCKX F., SCHIEPERS C.et al. — Clinical value of whole-body positron emission tomography with 18F-fluorodeoxyglucose in recurrent colorectal cancer.Br. J. Surg., 1994,81, 1666–1671.
DELBEKE D., VITOLA J., SANDLER M.P. — Staging recurrent metastatic colorectal carcinoma with PET.J. Nucl. Med., 1997,38, 1196–1201.
SCHIEPERS C., PENNINCKX F., DE VADDER N.et al. — Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging.Eur. J. Surg. Oncol., 1995,21, 517–522.
VALK P., ABELLA-COLUMNA E., TESAR R.D.et al. — Diagnostic accuracy and cost-effectiveness of whole-body PET imaging in recurrent colorectal cancer.J. Nucl. Med., 1996,37, 132P.
POUNDS T.R., VALK P.E., HASEMAN M.K.et al. — Whole-body PET-FDG imaging in diagnosis of recurrent colorectal cancer.J. Nucl. Med., 1995,36, 57P.
DAENEN F., HUSTINX R., PAULUS P.et al. — Detection of recurrent colorectal carcinoma with whole-body FDG PET.J. Nucl. Med., 1996,37, 261P.
ITO K., KATO T., OHTA T.et al. — Fluorine-18 fluoro-2-deoxyglucose positron emission tomography in recurrent rectal cancer: relation to tumour size and cellularity.Eur. J. Nucl. Med., 1996,23, 1372–1377.
KEOGAN M.T., LOWE V.J., BAKER M.E.et al. — Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging.Abdom. Imaging., 1997,22, 332–337.
TEMPERO M., BRAND R., HOLDEMAN K. — New imaging techniques in colorectal cancer.Sem. Oncol., 1995,22, 447–471.
FLANAGAN F.L., DEDASHTI F., OGUNBIYI O.A.et al. — Utility of FDG-PET for investigative unexplained plasma CEA clevation in patients with colorectal cancer.Ann. Sur., 1998,227, 319–323.
HABERKORN U., STRAUSS L., DIMITRAKOPOULOU A.et al. — PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy.J. Nucl. Med., 1991,32, 1485–1490.
ENGENHART R., KIMMIG B.N., STRAUB L.G.et al. — Therapy monitoring of presacral recurrences after high-dose irradiation: value of PET, CT, CEA and pain score.Strahlenther. Onkol., 1992, 168, 203–212.
MOEHLER M., DIMITRAKOPOULOU-STRAUSS A., OUTZLER F. — 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil.Cancer, 1998,83, 245–253.
DIMITRAKOPOULOU-STRAUSS A., STRAUSS L.G., SCHLAG P. — Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma.J. Nucl. Med., 1998,39, 1197–1202.
SYROTA A., DUQUESNOY N., PARAF A., KELLER-SHOHN C. — The role of positron emission tomography in the detection of pancreatic disease.Radiology, 1982,143, 249–253.
KIRCHNER P.T., RYAN J., ZALUTSKY M.et al. — Positron emission tomography for the evaluation of pancreatic disease.Semin. Nucl. Med., 1980,10, 374–391.
STOLLFUSS J.C., GLATTING G., FRIESS H.et al. — 2-(fluorine-18)-fluoro-2-deoxy-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.Radiology, 1995,195, 339–344.
INOKUMA T., TAMAKI N., TORIZUKA T.et al. — Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US.Radiology, 1995,195, 345–352.
FRIESS H., LANGHANS J., EBERT M.et al. — Diagnosis of pancreatic cancer by 2 [18F]-fluoro-2-deoxy-d-glucose positron emission tomography.Gut, 1995,365, 771–777.
BARES R., KLEVER P., HAUPTMANN S.et al. — F-18 Fluorodeoxyglucose PETin vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.Radiology, 1994,192, 79–86.
ZIMNY M., BARES R.N., FASS J.et al. — Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases.Eur. J. Nucl. Med., 1997,24, 678–682.
KEIDING S., HANSEN S.B.N., RASMUSSEN H.H.et al. — Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography.Hepatology, 1998,28, 700–706.
SHREVE P.D. — Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease.Eur. J. Nucl. Med., 1998,25, 259–264.
BARETTO A., DE BARSY C., PHAM T.et al. —, Tomographie à émission de positrons au 18FDG dans les cancers de l’œsophage.Med. Nucl., 1998, sous presse.
LUKETICH J.D., SCHAUER P.R., CIDIS MELTZER C.et al. — Role of positron emission tomography in staging esophageal cancer.Ann. Thorac. Surg., 1997,64, 765–769.
RANKIN S.C., TAYLOR H., COOK G.J.R., MASON R. — Computed tomography and positron emission tomography in the preoperative staging of oesophageal carcinoma.Clin. Radiology, 1998,53, 659–665.
KOLE S.C., PLUKKER J.T., NIEWEG O.E., VAALBURG W. — Positron emission tomography for staging of oesophageal and gastroesophageal malignancy.Brit. J. Cancer, 1998,78, 521–527.
FLANAGAN F.L., DEHDASHTI F.H., SIEGEL B.A.et al. — Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography.A.J.R., 1997,168, 417–424.
BLOCK M.I., PATTERSON A., SUNDARESAN R.S.et al. — Improvement in staging of esophageal cancer with the addition of positron emission tomography.Ann. Thorac., 1997,64, 770–777.
TORIZUKA T., TAMAKI N., INOKUMA T.et al. — Value of fluorine-18 FDG-PET to monitor hepatocellular carcinoma after interventional therapy.J. Nucl. Med., 1994,35, 1965–1969.
TORIZUKA T., TAMAKI N., INOKUMO T.et al. —In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET.J. Nucl. Med., 1995,36, 1811–1817.
HUSTINX R., PAULUS P., JACQUET N.et al. — Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases.Ann. Oncol., 1998,9, 397–401.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Rigo, P., Alberini, J.L., Hustinx, R. et al. Intérêt de la tomographie à émission de positrons dans l’évaluation des tumeurs gastro-intestinales. Acta Endosc 29, 129–138 (1999). https://doi.org/10.1007/BF03020280
Issue Date:
DOI: https://doi.org/10.1007/BF03020280